Concurrent EGFR and KRAS mutations in non-small cell lung cancer: Challenging the paradigm of linear targeted therapy. J Curr Biomed Rep [Internet]. 2025 Jun. 30 [cited 2026 Jun. 6];6(2):45-6. Available from: https://mail.jcbior.com/index.php/JCBioR/article/view/299